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Background: 2-Deoxy-D-glucose is an inhibitor of glycolysis, which is protective in animal models of brain
pathology, but the mechanisms of this protection are unclear. We examined whether, when and how deoxyglucose
protects neurons in co-culture with astrocytes and microglia. Microglia are brain macrophages, which can damage
neurons in inflammatory conditions.
Methods: Deoxyglucose was added to primary cultures of microglia and astrocytes from rat cortex, or neurons and
glia from rat cerebellum, or the BV-2 microglial cell line, and cell death and cell functions were evaluated.
Results: Surprisingly, addition of deoxyglucose induced microglial loss and prevented spontaneous neuronal loss in
long-term cultures of neurons and glia, while elimination of microglia by L-leucine-methyl ester prevented the
deoxyglucose-induced neuroprotection. Deoxyglucose also prevented neuronal loss induced by addition of amyloid
beta or disrupted neurons (culture models of Alzheimer’s disease and brain trauma respectively). However,
deoxyglucose greatly increased the neuronal death induced by hypoxia. Addition of deoxyglucose to pure microglia
induced necrosis and loss, preceded by rapid ATP depletion and followed by phagocytosis of the microglia.
Deoxyglucose did not kill astrocytes or neurons.
Conclusions: We conclude that deoxyglucose causes microglial loss by ATP depletion, and this can protect
neurons from neurodegeneration, except in conditions of hypoxia. Deoxyglucose may thus be beneficial in brain
pathologies mediated by microglia, including brain trauma, but not where hypoxia is involved.
Keywords: Neurodegeneration, Glycolysis, Neuroinflammation, Brain trauma, Brain ischemia, Alzheimer’s disease,
Energetics, Glia, Microglia, GlucoseBackground
2-Deoxy-D-glucose (DOG) is a glucose analogue that enters
cells and the brain via glucose transporters, and is phos-
phorylated by hexokinase to deoxyglucose-6-phosphate,
which then inhibits glycolysis at hexokinase and glucose-6-
phosphate isomerase [1]. DOG can thus kill cells that are
reliant on glycolysis, such as some cancer cells, via ATP de-
pletion without killing cells that can derive sufficient energy
from mitochondria, such as neurons [2]. DOG has been
extensively tested as a potential therapeutic agent in can-
cer specifically killing tumors cells via inhibition of gly-
colysis [1,2].
Perhaps more surprisingly, DOG can prevent neurode-
generation in the brains of animals subjected to a variety* Correspondence: gcb3@cam.ac.uk
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article, unless otherwise stated.of insults, including chemical or electrical induction of
epileptic seizures [3,4], a neurotoxin (iminodipropionitrile)
[5], brain radiotherapy [6], an inducer of Parkinsonism
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [7] and a
triple transgenic model of Alzheimer’s disease [8]. DOG
rapidly enters the brain and brain cells of healthy humans,
and thus its derivatives are widely used to image brain me-
tabolism [9]. DOG is also reasonably well tolerated by the
body at concentrations that protect the brain [6,10]. DOG
has thus been proposed as a therapy for a broad range of
brain pathologies and even ageing [11], but the mechan-
ism by which DOG protects the brain is unclear.
We investigate here whether DOG is protective or toxic
to neurons in culture, and the mechanisms involved. Sur-
prisingly, we find that DOG is very protective to neurons
in a variety of conditions by depleting microglia, but, un-
surprisingly, is toxic to neurons in hypoxic conditions.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tral nervous system [12]. Once activated by inflammatory
or pathological changes in the surrounding microenviron-
ment microglia can become toxic and/or protective to
nearby neurons [13-15]. The neurotoxicity of activated
microglia may contribute to a variety of brain pathologies
such as stroke, trauma, meningitis, epilepsy, motor neuron
disease, Parkinson’s disease and Alzheimer’s disease [13,15].
Alzheimer’s disease is characterized by amyloid pla-
ques (mainly consisting of aggregated amyloid beta (Aβ))
and tau tangles, accompanied by microglial activation
and progressive loss of neurons and synapses, which are
thought to cause the progressive dementia. Micromolar
levels of Aβ can induce direct neurotoxicity, but nanomo-
lar levels of Aβ induce neuronal loss mediated by micro-
glia, so that removal of microglia prevents Aβ-induced
neurotoxicity [16,17]. Brain trauma can also invoke sec-
ondary, delayed neuronal damage mediated by microglia
[18,19]. In brain slices or long-term cultures of microglia
and neurons, spontaneous loss of neurons mediated by
microglia can also occur if microglial activation is not re-
strained [20,21]. Understanding how to limit microglial
neurotoxicity may thus be important in treating a wide
variety of brain pathologies.
The cellular bioenergetics of microglia has been little
studied, and this is the first report that inhibition of gly-
colysis with DOG can kill microglia.
Methods
Materials
All chemicals and reagents were purchased from Sigma
(St Louis, MO, USA) except cell culture reagents (PAA,
Piscataway, NJ, USA), Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA, USA), Aβ1–42 (EZBiolab,
Carmel, IN, USA), Alexa fluor-488-labelled Griffonia
Simplicifolia isolectin B4 (Invitrogen), BCA protein assay
(Pierce, Rockford, IL, USA), rat tumor necrosis factor alpha
(TNFα) quantikine enzyme-linked immunosorbent assay
kit (R&D Systems, Minneapolis, MN, USA), ATP Biolumin-
escence Assay Kit (Roche, Basel, Switzerland), ZVal-Ala-D,
L-Asp(OMe)-fluoromethylketone and bocaspartyl (OMe)-
fluoromethylketone (Bachem, Bubendorf, Switzerland), and
5 μm fluorescent microspheres (Spherotec, Lake Forest, IL,
USA).
Cell culture
All experiments were performed in accordance with the
UK Animals (Scientific Procedures) Act (1986) and were
approved by the Cambridge University local ethical com-
mittee. Primary mixed neuronal/glial cultures were pre-
pared from cerebella of postnatal day 5 to 7 Wistar rats
(male and female) as described previously [22]. The ap-
proximate composition of the mixed cultures is 85 ± 5%
neurons, 7 ± 3% astrocytes, and 5 ± 3% microglia. Neuronswere plated at a density of 5 × 105 cells/24-well plate. Pure
microglia and glial cultures were prepared as described
previously [23]. Glial cells were plated at a density of 2 ×
105 cells/24-well plate. Glial cells were also seeded at a
high density into 75 cm3 flasks to allow the extraction of
pure microglia at 7 to 9 days in vitro (DIV). Microglia-
depleted cultures were obtained by adding 50 mML-leu-
cine-methyl ester (LME) for 4 hours [24,25]. The murine
microglial cell line BV-2 (passage < 30) was maintained in
a glia medium consisting of Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine
serum (PAA) in 75 cm2 flasks (Nalge Nunc, Penfield, New
York, USA) at 37°C, 5% carbon dioxide.
Cell treatments
Cultures were treated at 7 to 9 DIV. Cells were treated
with 250 nM Aβ1–42 prepared as described previously [17].
DOG was used at a final concentration of 10 mM. Cyto-
chalasin D was added at a final concentration of 1 μM for
6 hours.
Disrupted neurons
Addition of disrupted neurons to mixed neuronal–glial
cultures was used to model brain trauma. Disrupted neu-
rons were obtained by taking a live neuronal–glial culture
(prepared as above, mostly neurons), replacing the culture
medium with a low volume of phosphate-buffered saline,
scratching the cells with a cell scraper to disrupt processes,
scraping the cells to displace them from the surface, and
passing cells 10 times through a 0.4 mm× 13 mm syringe
needle. The total protein content was measured by BCA
protein assay (Pierce). Then 30 μg disrupted neurons (ap-
proximately 1.7 × 105 cells) were added to each well of live
neuronal–glial cultures in a 24-well plate to mimic trau-
matic brain injury.
Hypoxia treatment
Neuronal–glial cultures were placed in a Modular Incuba-
tor Chamber (MIC-101; Billups-Rothenberg, San Diego,
CA, USA) and the chamber was flushed either with a hyp-
oxic gas mixture (2% oxygen, 5% carbon dioxide, 93% ni-
trogen) and sealed or left in normoxic conditions (21%
oxygen, 5% carbon dioxide, 74% nitrogen), and both of
these samples placed in the same carbon dioxide incuba-
tor at 37°C for 12 hours. The percentage of oxygen was
checked with an oxymeter at the beginning and the end of
the hypoxia period. At the end of the hypoxic or normoxic
period, plates from the hypoxic chamber were removed
and placed in the incubator for reoxygenation for 4 days
together with normoxic plates.
Phagocytosis assay
Pure microglial cultures were plated at a density of 1 × 105
cells in poly-L-lysine-coated 24-well plates and treated
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5 μm carboxylate-modified latex microspheres were added
(diluted 1:2) for 2 hours and then washed with phosphate-
buffered saline to remove the excess. Images were
taken with a Leica DMI 6000 microscope (Leica, Solms,
Germany) and bead uptake was evaluated.
Cell density quantification
Cell densities (number of live neurons, live microglia,
apoptotic and necrotic cells) were assessed in cultures at
different time points depending on the experiment. For
live cell counts, cultures were incubated for 20 minutes
with the nuclear stains Hoechst 33342 (10 μg/ml, to stain
nuclei), propidium iodide (1 μg/ml, to stain nuclei of nec-
rotic cells) and Alexa 488-tagged isolectin-B4 (1 μg/ml, to
stain microglia). Cell densities were assessed using a Leica
DMI 6000 microscope (20× magnification, field size =
1.9 × 105 μm2; Leica). Apoptotic neurons were identified
by chromatin condensation of their nuclei. Necrotic cells
were identified by propidium iodide staining of their nu-
clei. Only propidium iodide-negative cells with nuclear
condensation were counted as apoptotic. Cells that were
not necrotic or apoptotic were counted as live. Microglia
were identified by isolectin-B4 staining. Astrocytes were
identified by flat shape and large, bean-shaped nuclear
morphology. Neurons were identified by small, round cell
bodies and neuronal processes.
TNFα measurement
The inflammatory mediator TNFα was measured using a
rat TNFα quantikine enzyme-linked immunosorbent assay
kit (R&D Systems) according to the provided protocol.
Values were expressed as picograms per milliliter.
ATP measurement
ATP was determined luminometrically (Jade luminometer;
Labtech International, Uckfield, East Sussex, UK) using an
ATP Bioluminescence Assay Kit (Roche) according to the
provided protocol. Briefly, pure microglia was used
24 hours after plating, at a density of 1 × 105 cells/well in
poly-L-lysine-coated 24-well plates. Before treatment, cul-
ture medium was removed to leave 200 μl/well and then
10 mM DOG was added for 1 hour. The same volume of
lysis buffer was then added, and 100 μl of the mix added
to 100 μl luciferase in the luminometer and the light emis-
sion measured. ATP concentrations were expressed as
relative light units.
Flow cytometry
Viability of BV-2 cells exposed to 10 mM DOG for 0, 3,
6, 24 or 48 hours was analyzed by flow cytometry (BD
Accuri C6 flow cytometer; BD, Franklin Lakes, NJ, USA)
with Annexin V (fluorescein isothiocyanate labeled) and
propidium iodide. Then 10,000 events were collected perwell and two wells per condition in at least three inde-
pendent experiments to quantify the total number of cells,
the number of Annexin V-positive cells (both propidium
iodide-positive and propidium iodide-negative) and the
number of propidium iodide-positive cells (both Annexin
V-positive and Annexin V-negative).Statistics
Four microscopic fields per well in two wells per condition
were quantified in at least three independent experiments
(on different cultures from different animals). Statistical
analysis was performed using SPSS software (SPSS Inc.,
Chicago, IL, USA). Normality of data was verified by
Kolmogorov–Smirnov test. Means among groups were
compared by one-way analysis of variance and post-hoc
Bonferroni test when data were normally distributed. If
the data were not normally distributed, then the Kruskal–
Wallis test was used to compare differences among
groups. The Mann–Whitney U test was used to determine
significant differences between pairs of variables that did
not follow a normal distribution, and the t test for nor-
mally distributed data. Graphs are expressed as means ±
standard error of the mean. Results were considered sig-
nificant at P < 0.05.Results
Deoxyglucose prevents neuronal loss mediated by microglia
To test whether DOG was neurotoxic or neuroprotec-
tive, we added 10 mM DOG to primary co-cultures of
neurons and glia from rat cerebellum for 96 hours (from
7 to 11 DIV), and observed that there was an apparent
increase in the density of live neurons compared with
the untreated condition (Figure 1A,D). The density of
live microglia substantially decreased over 96 hours of
DOG treatment (Figure 1B) but there was no effect on
astrocytes (Figure 1C). Thus, in response to DOG, the
density of neurons apparently increased by about 30%
(relative to untreated cultures) and microglia were al-
most eliminated, while astrocytes were unaffected. The
effect on neuronal density was dependent on the time of
incubation with DOG (Figure 2B), with more live neu-
rons surviving with longer treatments with DOG.
The apparent increase in neuronal density induced by
DOG could be due to preventing any spontaneous neur-
onal loss occurring in the untreated cultures, because long-
term culture of neurons in the presence of microglia can
result in spontaneous neuronal loss [20,21]. To test whether
spontaneous neuronal loss was occurring in the untreated
cultures, we quantified neuronal density between 7 and 11
DIV, and confirmed that neuronal loss was occurring in the
untreated cultures (from 407.5 ± 43.5 to 293.5 ± 4.5). We
imaged the same cells at 7 DIV and at 11 DIV, confirming
that there is a loss of neurons (Figure 1E).
Figure 1 Deoxyglucose prevents spontaneous neuronal loss in vitro. (A) Density of live, necrotic and apoptotic neurons in neuronal–glial
cultures at 11 days in vitro (DIV) depicted ±10 mM deoxyglucose added at 7 DIV. (B) Density of live microglia in the same experiment. (C) Density of
live astrocyes in the same experiment. (D) Sample fluorescent images of the same experiment stained with Hoescht 33342 to identify nuclei. (E) The
same untreated field imaged in phase contrast brightfield at 7 and 11 DIV, showing neuronal loss. Data presented as mean ± standard error of the
mean for≥ 3 independent experiments. Statistically significant differences between live neuronal densities: ***P < 0.001, ****P < 0.0001.
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neuronal loss over time, we treated the neuronal–glial
cultures with 50 mM LME for 4 hours to specifically
eliminate microglia [25]. We observed that when micro-
glia were eliminated at 7 DIV, there were more live neu-
rons by 11 DIV, and that addition of DOG from 7 to 11
DIV no longer increased neuronal density in the absence
of microglia (Figure 2A). Elimination of microglia is thus
sufficient to prevent spontaneous neuronal loss in cul-
ture and to prevent the protection of those neurons byFigure 2 Effects of deoxyglucose on neuronal density. (A) Neuronal–g
remove microglia, and then treated ±10 mM deoxyglucose (DOG) for 96 h
depletion of microglia with LME prevented the neuroprotective effect of D
DOG at 7, 8, 9 or 10 days in vitro (DIV), and then total (live and dead) neuro
error of the mean for≥ 3 independent experiments. Statistically significantDOG. As DOG also depletes microglia from the cultures
(Figure 1B), the neuronal protection by DOG appears to
be due to DOG depleting the microglia and thereby pre-
venting the spontaneous neuronal loss.
Deoxyglucose prevents inflammatory neuronal loss
induced by amyloid beta or trauma, but exacerbates
hypoxic neuronal death
To test whether DOG may be neuroprotective or neuro-
toxic in particular neurological diseases and conditions,lial cultures were treated ± L-leucine-methyl ester (LME) for 4 hours to
ours, and total (live and dead) neuronal density was counted. Prior
OG. (B) Neuronal–glial cultures were untreated or treated with 10 mM
nal density measured at 11 DIV. Data presented as mean ± standard
differences between total neuronal densities: *P < 0.05.
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that relate to Alzheimer’s disease, brain trauma and stroke.
We have previously reported that nanomolar levels of
Aβ induce neuronal loss over 3 days in neuronal–glial
co-cultures that is prevented if microglia are eliminated
by LME [17,26]. We thus tested whether DOG could
prevent this neuronal loss, and indeed found that 10 mM
DOG prevented the neuronal loss induced by 250 nM Aβ
(Figure 3A). Aβ-induced neuronal loss, when mediated by
microglia, can thus be prevented by DOG, presumably by
eliminating the microglia.
Brain trauma can cause delayed neuronal damage me-
diated by microglia [18,19]. We modeled brain trauma
in vitro by adding disrupted neurons to live neuronal–
glial co-cultures, and found that this increased the loss
of live neurons over 96 hours (Figure 3B). Disrupted
neurons were prepared by scraping and homogenizing
neuronal–glial cultures (which are 85% neurons), result-
ing in cellular debris and released content. Addition of
10 mM DOG prevented the neuronal loss induced by
disrupted neurons (Figure 3B). DOG might thus be neu-
roprotective in brain trauma by depleting microglia.
A number of brain pathologies, such as stroke, vascular
dementia and trauma, are associated with hypoxia, so
we tested whether DOG could prevent or exacerbate
hypoxia-induced neuronal death. Moreover, stroke can
be ischemic (decrease of blood flow), which can be
mimicked in vitro by combining hypoxia and glucose
deprivation with DOG. Neuronal–glial cultures were
exposed to hypoxia (2% oxygen for 12 hours) ± DOG
(10 mM) plus 4 days of reoxygenation. As previously,
there were significantly more live neurons when DOG
was added in normoxic (21% oxygen) conditions (Figure 4A)
associated with microglial depletion (Figure 4B). In the ab-
sence of DOG, hypoxia induced a small loss of live neurons
(Figure 4A). However, in the presence of DOG, hypoxia
induced massive neuronal death (Figure 4A), presumablyFigure 3 Deoxyglucose can prevent loss of live neurons induced by am
the neuronal loss induced by amyloid beta (Aβ; 250 nM for 96 hours). (B) DO
(30 μg protein for 96 hours – Trauma). Data presented as mean ± standard er
differences between live neuron densities:*P < 0.05, **P < 0.01, ***P < 0.001, **because during hypoxia neurons are more reliant on gly-
colysis for energy production. DOG can thus be neuropro-
tective or neurotoxic depending on conditions.
Although DOG decreased microglial levels at both 21%
and 2% oxygen, the decrease was less in the latter, hypoxic
conditions (Figure 4B). We do not know the reason for
this – perhaps oxygen-derived radicals are involved in the
cell death, or hypoxia upregulates remaining glycolysis, or
the neuronal death occurring in these conditions causes
microglial proliferation.
Microglia are killed by deoxyglucose via ATP depletion
and phagocytosis
DOG depleted microglia in neuronal–glial cultures over
96 hours (Figure 1B), so we tested whether DOG would
kill or deplete microglia in a glial culture (Figure 5A), a
pure microglial culture (Figure 5B) or the microglial cell
line BV-2 (Figure 6). Twenty-four hours of DOG treat-
ment caused a significant decrease in microglial density
in all three cultures and significant increases in micro-
glial necrosis (measured by propidium iodide uptake) in
glial cultures and the BV-2 cell line (Figures 5 and 6).
The decrease in microglial density in BV-2 cultures was
substantially greater with 10 mM DOG than with 1 or
5 mM DOG (Additional file 1: Figure S1), so we used
10 mM DOG in subsequent experiments. The proportion
of microglia that were chromatin condensed but had not
taken up propidium iodide (a measure of apoptosis) was
low in all conditions. The proportion of DOG-treated BV-
2 microglia that exposed phosphatidylserine (measured by
Annexin V binding; Figure 6C) increased with time, pre-
ceding the cells becoming necrotic (measured by propi-
dium iodide uptake; Figure 6D), which could be due to
apoptosis or energy depletion-induced phosphatidylserine
exposure.
We tested whether the broad-spectrum caspase
inhibitors ZVal-Ala-D,L-Asp(OMe)-fluoromethylketoneyloid beta and disrupted neurons. (A) Deoxyglucose (DOG) prevented
G prevented the neuronal loss induced by adding disrupted neurons
ror of the mean for≥ 3 independent experiments. Statistically significant
**P < 0.0001.
Figure 4 Deoxyglucose results in neuronal death with hypoxia. (A) Deoxyglucose increased the neuronal death induced by hypoxia (2% oxygen for
12 hours followed by 96 hours of normoxia; that is, 21% oxygen). (B) Density of live microglia in the previous experiment (A). Data presented as mean ±
standard error of the mean for≥ 3 independent experiments. *Live cells, #necrotic cells, +apoptotic cells: *, #, +P< 0.05, **P< 0.01, ****, ####, ++++P< 0.0001.
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DOG-induced death of microglia. However, there was no
such protection (Additional file 2: Table S1), suggesting
that apoptosis is not involved.
DOG can kill cancer cells by interfering with N-linked
glycosylation, which is reversible by exogenous addition
of mannose [27,28]. We tested whether addition of 2 mM
mannose for 48 hours could prevent DOG-induced
microglial loss in primary glial cultures, but found no
effect of mannose on microglia loss (Additional file 2:
Table S1).
DOG can activate sirtuins, such as Sirtuin 1, in cells
via inhibiting glycolysis and increasing NAD+ levels. Sir-
tuin 1 is a NAD+-dependent histone deacetylase that is
inhibited by nicotinamide. However, we found that nico-
tinamide (at 100, 300 or 600 μM) was not able to pre-
vent DOG-induced microglial death (Additional file 2:
Table S1), suggesting that sirtuins are not involved in
this death.
Autophagy can be activated by DOG in some cells [29].
We tested whether the autophagy inhibitor chloroquineFigure 5 Microglia are killed by deoxyglucose. (A) Glial cultures (contai
deoxyglucose (DOG) for the indicated times, and the density of live and de
microglia from rat cortex were treated ±10 mM DOG for the indicated time
were counted. Data presented as mean ± standard error of the mean for≥ 3
***P < 0.001, ****P < 0.0001.(10 or 25 μM) could prevent DOG-induced microglia
death, but found no effect (Additional file 2: Table S1).
DOG can deplete cellular ATP by inhibition of glycoly-
sis [1,2]. We therefore tested whether DOG could de-
plete ATP in microglia prior to any cell death or loss.
Indeed, we found that DOG caused marked ATP deple-
tion after just 1 hour of DOG treatment of pure, primary
microglia (Additional file 3: Figure S2A) or BV-2 microglia
(Figure 6B) prior to any increase in cell death (Figure 6D).
This suggests that DOG induces death of microglia by
ATP depletion, and that microglia are dependent on gly-
colysis for energy generation.
To test whether DOG could stimulate or inhibit the
activation of microglia prior to any significant microglial
death, we measured TNFα levels in the culture medium
of pure, primary microglia at 3 hours after addition of
10 mM DOG. We observed a small increase in TNFα
production/release (Additional file 3: Figure S2B) prior
to any increase in cell death (Figure 5B).
As the loss of microglia could be due to phagocytosis by
other microglia, we tested whether deoxyglucose couldning microglia and astrocytes) from rat cortex were treated ±10 mM
ad (necrotic plus apoptotic) microglia were counted. (B) Pure primary
s and the density of live and dead (necrotic plus apoptotic) neurons
independent experiments.*Live cells, #dead cells: *, #P < 0.05, **P < 0.01,
Figure 6 Deoxyglucose rapidly depletes ATP prior to microglial death. (A) BV-2 density at different time points (0, 1 hour, 3 hours, 6 hours,
24 hours, 48 hours) after addition of 10 mM deoxyglucose (DOG) measured by flow cytometry. (B) Cellular ATP levels determined with luciferin/
luciferase at the same time points. RLU, relative light units. (C) Percentage of Annexin V-positive BV-2 cells measured by flow cytometry at the same
time points. (D) Percentage of propidium iodide (PI)-positive BV-2 cells measured by flow cytometry at the same time points. Data presented as mean
± standard error of the mean for≥ 3 independent experiments.*P < 0.05, ***P < 0.001, ****P < 0.0001.
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glia were treated with 10 mM deoxyglucose for 21 hours
and then 5 μm carboxylate-modified latex microspheres
were added for 2 hours. We observed a very small increase
in phagocytosis of microspheres with DOG treatment
(Figure 7A).Figure 7 Microglial phagocytosis contributes to the loss of microglia
deoxyglucose (DOG; 10 mM) for 21 hours, and were then incubated with 5 μ
of beads phagocytosed per cell quantified. (B) The phagocytosis inhibitor cyt
the addition of DOG (10 mM) in glial cultures. Data presented as mean ± stan
*P < 0.05, **P < 0.01.Dead and dying cells can be rapidly removed by phago-
cytosis, and microglia are particularly active in this type of
phagocytosis [15]. To test whether phagocytosis was in-
volved in the microglial loss induced by DOG, we added an
inhibitor of phagocytosis: cytochalasin D (1 μM) together
with 10 mM DOG for 6 hours. Cytochalasin D delayed theinduced by deoxyglucose. (A) Pure primary microglia were treated ±
m carboxylate-modified latex microspheres for 2 hours, and the number
ochalasin D (1 μM) decreased the loss of microglia measured 6 hours after
dard error of the mean for≥ 3 independent experiments. *Total microglia:
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indicating that phagocytosis may be involved in the
microglial loss. Annexin V is a phosphatidylserine-binding
protein, which when added extracellularly can block phos
phatidylserine-mediated phagocytosis. However, addition
of Annexin V (at concentrations that we have previ-
ously found to block microglial phagocytosis: 100 nM)
could not prevent the microglial loss induced by DOG
(Additional file 2: Table S1), suggesting that eat-me sig-
nals other than phosphatidylserine are involved in the
phagocytosis of dying microglia by microglia.
Discussion
Addition of DOG depleted microglia, protected neurons
and had no effect on astrocyte viability. The mechanism
by which DOG depleted microglia appears to be mainly
via directly killing the microglia, probably via inhibition
of glycolysis and ATP depletion, inducing microglial ne-
crosis and their phagocytosis by other microglia. Although
DOG did increase the number of necrotic microglia, this
increase was less than the decrease in total microglial
numbers, suggesting that necrotic or prenecrotic cells are
removed rapidly by viable microglia. Consistent with this,
we found that DOG did not inhibit microglial phagocyt-
osis, and that inhibition of phagocytosis by cytochalasin D
delayed the DOG-induced microglial loss. It is not clear
why inhibition of glycolysis by DOG specifically kills
microglia and not neurons or astrocytes, although a simple
explanation would be that neurons derive most of their
ATP from mitochondria [30], while microglia/macro-
phages derive most of their ATP from glycolysis, particu-
larly when activated [31]. There are no previous reports
that DOG kills microglia.
The mechanism by which DOG protected neurons ap-
pears to be via depletion of microglia based on our findings
that DOG did deplete microglia, that depleting microglia
with LME also protected neurons, and that depleting
microglia with LME prevented DOG protecting neurons.
In the longer term, any DOG inhibition of microglial pro-
liferation might also contribute to microglial depletion.
DOG might in principle inhibit microglial activation – but
we found that DOG mildly increased TNFα levels and
phagocytosis, making this potential explanation for the
neuroprotection unlikely. DOG does not directly inhibit
the pentose phosphate pathway, but can indirectly perturb
it [32] or increase it by inhibiting glycolysis, which might
contribute to cell death, although this pathway is normally
thought to be protective. Recent evidence suggests that
modulating mitochondria can decrease the proinflamma-
tory status of microglia [33,34]. Park and colleagues found
that inhibition of mitochondrial fission and reactive oxygen
species generation attenuated the production of proinflam-
matory mediators [33]. On the other hand, Voloboueva and
colleagues observed that overexpressing a mitochondrialchaperone glucose-regulated protein 75 decreased micro-
glial activation [34].
DOG has shown some promise in treating animal models
of epilepsy [3,4], Alzheimer’s disease [8] and Parkinson’s
disease [7], and while other mechanisms are not excluded,
it is possible that DOG-induced depletion of microglia may
contribute to this protection in vivo. Obviously it would be
useful to know whether DOG therapy in vivo does in fact
deplete brain microglia, but there is currently no informa-
tion on this. DOG has been used to mimic the metabolic
effects of dietary restriction in reducing aging (for example
[7,11]), so it would be interesting to know whether dietary
restriction also depletes microglia in the brain because diet-
ary restriction has been shown to improve cognitive func-
tion in aged rodents and humans [35].
DOG prevented Aβ-induced neuronal loss, which we
have previously shown to be dependent on microglia
[17,26], so this is consistent with the DOG protection
being due to depletion of microglia. DOG prevented the
neuronal loss induced by disrupted neurons, presumably
by microglial depletion. DOG also protected against spon-
taneous neuronal loss in these neuronal–glial cultures.
We do not know what causes this spontaneous neuronal
loss, but in general it is more likely to occur with longer-
term culture (more DIV) and when there are more dead
neurons in the culture. As addition of disrupted/dead neu-
rons to the culture can induce neuronal loss, it may be
that this spontaneous neuronal loss is driven by dead neu-
rons present in the culture. Whatever the cause, our find-
ing that DOG can prevent this spontaneous neuronal loss
may be of practical value in culturing neurons in the
longer term.
Our finding that DOG does not protect against hypoxia-
induced neuronal loss, but rather greatly potentiates
hypoxia-induced neuronal death, is not surprising given
that inhibition of both glycolysis and mitochondrial respir-
ation will cause ATP depletion in all cells. However, this
does highlight the dangers of using DOG as a brain ther-
apy given that hypoxia occurs in a variety of brain patholo-
gies such as stroke, vascular dementia and trauma. On the
other hand, because brain hypoxia can be monitored non-
invasively in patients, this danger could in principle be
minimized. Also DOG can be protective against ischemic
damage if the brain is hyperglycemic by preventing exces-
sive lactate production in such conditions [36].Conclusions
We conclude that DOG causes microglial death by ATP
depletion, resulting in microglial loss by phagocytosis,
and this can protect neurons from inflammatory neuro-
degeneration. DOG may thus be beneficial in brain path-
ologies mediated by microglia, but not where hypoxia
is involved.
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Additional file 1: Figure S1. showing the effect of different doses
(1 mM, 5 mM, 10 mM) of DOG on BV-2 density measured by flow cytometry.
***P < 0.001.
Additional file 2: Table S1. presenting a list of the compounds tested
that did not prevent death of microglia induced by DOG. zVAD, ZVal-Ala-D,
L-Asp(OMe)-fluoromethylketone; BAF, bocaspartyl (OMe)-fluoromethylketone;
PS, phosphatidylserine.
Additional file 3: Figure S2. showing DOG rapidly depletes ATP and
inflammatory activates microglia. (A) ATP levels were determined in pure
primary microglia cultured from rat cortex and treated with DOG
(10 mM) for 1 hour. RLU, relative light units. (B) TNFα levels were
measured in the culture medium of pure primary microglia treated ±
10 mM deoxyglucose for 3 hours. Data presented as mean ± standard
error of the mean for ≥ 3 independent experiments.*P < 0.05, **P < 0.01.
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